Lessons learned from making and implementing vaccine recommendations in the U.S.

Vaccine

Volumn 33, Issue , 2015, Pages D78-D82

  Walton, L Reed ^a   Orenstein, Walter A ^b   Pickering, Larry K ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; VACCINE; WART VIRUS VACCINE;

ACTIVE IMMUNIZATION; ADVISORY COMMITTEE; ARTICLE; BRAIN DISEASE; COST; ERYTHEMA; FEBRILE CONVULSION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNIZATION; INTUSSUSCEPTION; LICENSING; PERCEPTION; PRIORITY JOURNAL; UNITED STATES; COMMUNITY CARE; ECONOMICS; PREVENTIVE HEALTH SERVICE; PSYCHOLOGY; TREATMENT REFUSAL; VACCINATION;

COMMUNITY HEALTH SERVICES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; TREATMENT REFUSAL; UNITED STATES; VACCINATION; VACCINES;

EID: 84950294245     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.036     Document Type: Article

References (49)

1. Recommended immunization schedules for persons aged 0 through 18 years. Accessed July 13, 2015. http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html.
2. Recommended adult immunization schedule. Accessed July 13, 2015. http://www.cdc.gov/vaccines/schedules/hcp/adult.html.
3. Smith J.C., Hinman A.R., Pickering L.K. History and evolution of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2014, 63:955-958.
4. Walton L.R., Orenstein W.A., Pickering L.K. The history of the United States Advisory Committee on Immunization Practices. Vaccine 2015, 33:405-414.
5. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999, 48(RR-02):1-23. CDC.
6. Prevention of rotavirus disease; guidelines for use of rotavirus vaccine. Pediatrics 1998, 102(6):1483-1491. Committee on Infectious Diseases, American Academy of Pediatrics. 10.1542/peds.102.6.1483.
7. Vaccine Adverse Event Reporting System. Accessed July 13, 2015. https://vaers.hhs.gov/index.
8. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999, 48(27):577-581. CDC.
9. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999, 48(43):1007. CDC.
10. McPhillips H.A., Davis R.L., Marcuse E.K., Taylor J.A. The rotavirus vaccine's withdrawal and physicians' trust in vaccine safety mechanisms. Arch Pediatr Adolesc Med 2001, 155(9):1051-1056. 10.1001/archpedi.155.9.1051.
11. Iwamoto M., Saari T.N., McMahon S.R., et al. A survey of pediatricians on the reintroduction of a rotavirus vaccine. Pediatrics 2003, 112(1):e6-e10. 10.1542/peds.112.1.e6.
12. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009, 58(RR02):1-25. CDC.
13. Yih W.K., Lieu T.A., Kulldorff M., et al. Intussusception risk after rotavirus vaccination in U.S. Infants. N Engl J Med 2014, 370(6):503-512. 10.1056/NEJMoa1303164.
14. Griffin M.R., Ray W.A., Mortimer E.A., Fenichel G.M., Schaffner W. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA 1990, 263(12):1641-1645. 10.1001/jama.1990.03440120063038.
15. Mnookin S. The Panic Virus: A True Story of Medicine, Science, and Fear 2011, Simon & Schuster, New York.
16. Reyes I., Hsieh D.T., Laux L.C., Wilfong A.A. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics 2011, 128(3):e699-e702. 10.1542/peds.2010-0887.
17. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46(RR07):1-25. CDC.
18. Klein N.P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012, 367:1012-1019. 10.1056/NEJMoa1200850.
19. Witt M.A., Arias L., Katz P.H., Truong E.T., Witt D.J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large U.S. cohort. Clin Infect Dis 2013, 56(9):1248-1254. 10.1093/cid/cit046.
20. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54(12):1730-1735. 10.1093/cid/cis287.
21. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR03):1-34. CDC.
22. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013, 62(07):131-135. CDC.
23. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2012, 61(40). CDC, 826-819.
24. Moore M.R., Link-Gelles R., Schaffner W., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015, 15(3):301-309. 10.1016/S1473-3099(14)71081-3.
25. Lexau C.A., Lynfield R., Danila R. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(16):2043-2051. 10.1001/jama.294.16.2043.
26. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014, 63(37):822-825. CDC.
27. Lopman B.A., Curns A.T., Yen C., Parashar U.D. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011, 204(7):980-986. 10.1093/infdis/jir492.
28. Anderson E.J., Shippee D.B., Weinrobe M.H., et al. Indirect protection from rotavirus by pediatric rotavirus vaccination. Clin Infect Dis 2013, 56(6):755-760. 10.1093/cid/cis1010.
29. Rodewald L.E., Orenstein W.A., Mason D.D., Cochi S.L. Vaccine supply problems: a perspective of the Centers for Disease Control and Prevention. Clin Infect Dis 2006, 42(Suppl 3):S104-S110. 10.1086/499587.
30. Hinman A.R., Orenstein W.A., Santoli J.M., Rodewald L.E., Cochi S.L. Vaccine shortages: history, impact, and prospects for the future. Annu Rev Public Health 2006, 27:235-259. 10.1146/annurev.publhealth.27.021405.102248.
31. Notice to readers: limited supply of meningococcal conjugate vaccine, recommendation to defer vaccination of persons aged 11-12 years. MMWR Morb Mortal Wkly Rep 2006, 55(20). CDC, 576-568.
32. ®). MMWR Morb Mortal Wkly Rep 2007, 56(50):1318-1320. CDC.
33. Invasive Haemophilus influenza Type B disease in five young children - Minnesota, 2008. MMWR Morb Mortal Wkly Rep 2009, 58(3):58-60. CDC.
34. Santibanez T.A., Shefer A., Briere E.C., Cohn A.C., Groom A.V. Effects of a nationwide Hib vaccine shortage on vaccination coverage in the United States. Vaccine 2012, 30(5):941-947. 10.1016/j.vaccine.2011.11.075.
35. Markowitz L.E., Preblud S.R., Orenstein W.A., et al. Patterns of transmission in measles outbreaks in the United States, 1985-1986. N Engl J Med 1989, 320:75-81. 10.1056/NEJM198901123200202.
36. Orenstein W.A. The role of measles elimination in development of a national immunization program. Pediatr Infect Dis J 2006, 25(12):1093-1101. 10.1097/01.inf.0000246840.13477.28.
37. Measles prevention: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Suppl 1989, 38(S-9):1-18. CDC.
38. Measles: reassessment of the current immunization policy. Pediatrics 1989, 84:1110-1113. American Academy of Pediatrics Committee on Infectious Diseases.
39. Holman D.M., Benard V., Roland K.B., Watson M., Liddon N., Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 2014, 168(1):76-82. 10.1001/jamapediatrics.2013.2752.
40. Javanbakht M., Stahlman S., Walker S., et al. Provider perceptions of barriers and facilitators of HPV vaccination in a high-risk community. Vaccine 2012, 30(30):4511-4516. 10.1016/j.vaccine.2012.04.062.
41. Hughes C.C., Jones A.L., Feemster K.A., Fiks A.G. HPV vaccine decision making in pediatric primary care: a semi-structured interview study. BMC Pediatr 2011, 11:74. 10.1186/1471-2431-11-74.
42. Vadaparampil S.T., Malo T.L., Kahn J.A., et al. Physicians' human papillomavirus vaccine recommendations, 2009 and 2011. Am J Prev Med 2014, 46(1):80-84. 10.1016/j.amepre.2013.07.009.
43. Forster A.S., Marlow L.A.V., Stephenson J., et al. Human papillomavirus vaccination and sexual behaviour: cross-sectional and longitudinal surveys conducted in England. Vaccine 2012, 30(33):4939-4944. 10.1016/j.vaccine.2012.05.053.
44. Mayhew A., Mullins T.L.K., Ding L., et al. Risk perceptions and subsequent sexual behaviors after HPV vaccination in adolescents. Pediatrics 2014, 133(3):404-411. 10.1542/peds.2013-2822.
45. Jena A.B., Goldman D.P., Seabury S.A. Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females. JAMA Intern Med 2015, 175(4):617-623. http://archinte.jamanetwork.com/article.aspx?articleid=2109856.
46. Schwartz J.L., Mahmoud A. A half-century of prevention-the Advisory Committee on Immunization Practices. N Engl J Med 2014, 371:1953-1956. 10.1056/NEJMp1410049.
47. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49(RR05):1-22. CDC.
48. Miller M.A., Sutter R.W., Strebel P.M., Hadler S.C. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA 1996, 276(12):967-971. 10.1001/jama.1996.03540120045032.
49. Pickering L.K., Walton L.R. Vaccines in the pipeline: the path from development to use in the United States. Pediatric Annals 2013, 42(8):146-152. 10.3928/00904481-20130723-08.